Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease

Young Jin Youn, Jun Won Lee, Sung Gyun Ahn, Seung Hwan Lee, Hyunmin Choi, Cheol Woong Yu, Young Joon Hong, Hyuck Moon Kwon, Myeong Ki Hong, Yangsoo Jang, Junghan Yoon

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background There are conflicting data on the use of cilostazol as triple antiplatelet therapy (TAPT) for improving clinical outcomes after drug-eluting stent implantation. We aimed to evaluate whether 3-month use of cilostazol in addition to dual antiplatelet therapy (DAPT) improved clinical outcomes in patients with long or multivessel coronary artery disease (CAD) after biolimus-eluting stent (BES) implantation. Methods Patients (n = 630) who had been successfully treated with BES implantation for lesions with ≥28 mm in stent length or ≥2 stents for different coronary arteries were enrolled in this prospective randomized multicenter trial. All patients were randomly assigned to receive either DAPT (aspirin and clopidogrel for 12 months, n = 314) or TAPT (DAPT plus 3-month cilostazol use, n = 316). The primary end point was a device-oriented composite consisting of cardiac death, myocardial infarction (not clearly attributable to a nontarget vessel), and ischemia-driven target lesion revascularization at 1-year follow-up. Results A total of 314 patients in DAPT and 308 patients in TAPT were analyzed. Multivessel CAD was present in 65.7% of patients. Stents ≥28 mm in length were implanted in 58.1% of lesions. There were no significant differences in baseline and angiographic characteristics between the 2 groups. The primary end point was similar between the 2 groups (2.3% in DAPT vs 1.9% in TAPT, log-rank P =.799). Conclusions In patients treated with BES implantation for long or multivessel CAD, 3 months of cilostazol use in addition to DAPT did not improve clinical outcome at 1-year follow-up.

Original languageEnglish
JournalAmerican Heart Journal
Volume167
Issue number2
DOIs
Publication statusPublished - 2014 Feb 1
Externally publishedYes

Fingerprint

Multicenter Studies
Stents
Coronary Artery Disease
Therapeutics
clopidogrel
cilostazol
Drug-Eluting Stents
Aspirin
Coronary Vessels
Ischemia
Myocardial Infarction
Equipment and Supplies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. / Youn, Young Jin; Lee, Jun Won; Ahn, Sung Gyun; Lee, Seung Hwan; Choi, Hyunmin; Yu, Cheol Woong; Hong, Young Joon; Kwon, Hyuck Moon; Hong, Myeong Ki; Jang, Yangsoo; Yoon, Junghan.

In: American Heart Journal, Vol. 167, No. 2, 01.02.2014.

Research output: Contribution to journalArticle

Youn, Young Jin ; Lee, Jun Won ; Ahn, Sung Gyun ; Lee, Seung Hwan ; Choi, Hyunmin ; Yu, Cheol Woong ; Hong, Young Joon ; Kwon, Hyuck Moon ; Hong, Myeong Ki ; Jang, Yangsoo ; Yoon, Junghan. / Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. In: American Heart Journal. 2014 ; Vol. 167, No. 2.
@article{f6d8884ec0b14342926d0d665fa24802,
title = "Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease",
abstract = "Background There are conflicting data on the use of cilostazol as triple antiplatelet therapy (TAPT) for improving clinical outcomes after drug-eluting stent implantation. We aimed to evaluate whether 3-month use of cilostazol in addition to dual antiplatelet therapy (DAPT) improved clinical outcomes in patients with long or multivessel coronary artery disease (CAD) after biolimus-eluting stent (BES) implantation. Methods Patients (n = 630) who had been successfully treated with BES implantation for lesions with ≥28 mm in stent length or ≥2 stents for different coronary arteries were enrolled in this prospective randomized multicenter trial. All patients were randomly assigned to receive either DAPT (aspirin and clopidogrel for 12 months, n = 314) or TAPT (DAPT plus 3-month cilostazol use, n = 316). The primary end point was a device-oriented composite consisting of cardiac death, myocardial infarction (not clearly attributable to a nontarget vessel), and ischemia-driven target lesion revascularization at 1-year follow-up. Results A total of 314 patients in DAPT and 308 patients in TAPT were analyzed. Multivessel CAD was present in 65.7{\%} of patients. Stents ≥28 mm in length were implanted in 58.1{\%} of lesions. There were no significant differences in baseline and angiographic characteristics between the 2 groups. The primary end point was similar between the 2 groups (2.3{\%} in DAPT vs 1.9{\%} in TAPT, log-rank P =.799). Conclusions In patients treated with BES implantation for long or multivessel CAD, 3 months of cilostazol use in addition to DAPT did not improve clinical outcome at 1-year follow-up.",
author = "Youn, {Young Jin} and Lee, {Jun Won} and Ahn, {Sung Gyun} and Lee, {Seung Hwan} and Hyunmin Choi and Yu, {Cheol Woong} and Hong, {Young Joon} and Kwon, {Hyuck Moon} and Hong, {Myeong Ki} and Yangsoo Jang and Junghan Yoon",
year = "2014",
month = "2",
day = "1",
doi = "10.1016/j.ahj.2013.08.028",
language = "English",
volume = "167",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease

AU - Youn, Young Jin

AU - Lee, Jun Won

AU - Ahn, Sung Gyun

AU - Lee, Seung Hwan

AU - Choi, Hyunmin

AU - Yu, Cheol Woong

AU - Hong, Young Joon

AU - Kwon, Hyuck Moon

AU - Hong, Myeong Ki

AU - Jang, Yangsoo

AU - Yoon, Junghan

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Background There are conflicting data on the use of cilostazol as triple antiplatelet therapy (TAPT) for improving clinical outcomes after drug-eluting stent implantation. We aimed to evaluate whether 3-month use of cilostazol in addition to dual antiplatelet therapy (DAPT) improved clinical outcomes in patients with long or multivessel coronary artery disease (CAD) after biolimus-eluting stent (BES) implantation. Methods Patients (n = 630) who had been successfully treated with BES implantation for lesions with ≥28 mm in stent length or ≥2 stents for different coronary arteries were enrolled in this prospective randomized multicenter trial. All patients were randomly assigned to receive either DAPT (aspirin and clopidogrel for 12 months, n = 314) or TAPT (DAPT plus 3-month cilostazol use, n = 316). The primary end point was a device-oriented composite consisting of cardiac death, myocardial infarction (not clearly attributable to a nontarget vessel), and ischemia-driven target lesion revascularization at 1-year follow-up. Results A total of 314 patients in DAPT and 308 patients in TAPT were analyzed. Multivessel CAD was present in 65.7% of patients. Stents ≥28 mm in length were implanted in 58.1% of lesions. There were no significant differences in baseline and angiographic characteristics between the 2 groups. The primary end point was similar between the 2 groups (2.3% in DAPT vs 1.9% in TAPT, log-rank P =.799). Conclusions In patients treated with BES implantation for long or multivessel CAD, 3 months of cilostazol use in addition to DAPT did not improve clinical outcome at 1-year follow-up.

AB - Background There are conflicting data on the use of cilostazol as triple antiplatelet therapy (TAPT) for improving clinical outcomes after drug-eluting stent implantation. We aimed to evaluate whether 3-month use of cilostazol in addition to dual antiplatelet therapy (DAPT) improved clinical outcomes in patients with long or multivessel coronary artery disease (CAD) after biolimus-eluting stent (BES) implantation. Methods Patients (n = 630) who had been successfully treated with BES implantation for lesions with ≥28 mm in stent length or ≥2 stents for different coronary arteries were enrolled in this prospective randomized multicenter trial. All patients were randomly assigned to receive either DAPT (aspirin and clopidogrel for 12 months, n = 314) or TAPT (DAPT plus 3-month cilostazol use, n = 316). The primary end point was a device-oriented composite consisting of cardiac death, myocardial infarction (not clearly attributable to a nontarget vessel), and ischemia-driven target lesion revascularization at 1-year follow-up. Results A total of 314 patients in DAPT and 308 patients in TAPT were analyzed. Multivessel CAD was present in 65.7% of patients. Stents ≥28 mm in length were implanted in 58.1% of lesions. There were no significant differences in baseline and angiographic characteristics between the 2 groups. The primary end point was similar between the 2 groups (2.3% in DAPT vs 1.9% in TAPT, log-rank P =.799). Conclusions In patients treated with BES implantation for long or multivessel CAD, 3 months of cilostazol use in addition to DAPT did not improve clinical outcome at 1-year follow-up.

UR - http://www.scopus.com/inward/record.url?scp=84892792224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892792224&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2013.08.028

DO - 10.1016/j.ahj.2013.08.028

M3 - Article

VL - 167

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 2

ER -